Replies to post #165043 on Biotech Values

[DewDiligence]

PTLA had $235M of cash at 6/30/13, burning approximately $25M during 2Q13:

http://finance.yahoo.com/news/portola-pharmaceuticals-reports-second-quarter-115500633.html

For PTLA investors, liquidity is clearly not the main concern. Rather, the main concern should be the shortcomings of the phase-3 Betrixaban program (#msg-89332563, #msg-89290904).